Andre Goy, MD
Medical Oncology · Hackensack, NJNPI 1215992912
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,518 of the $53,358 with a category attached, or 87.2%. Gilead accounts for 61.6% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $18,597 and has fallen 99.3% since, to $138 in 2025. Among medical oncology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $970.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$33K
- AstraZeneca$10K
- Pharmacyclics LLC, An Abbvie Company$3K
- F. Hoffmann-la Roche AG$2K
- Johnson & Johnson$2K
- Novartis$1K
- plus $1K from 10 others
Across 302 payments — averaging $8204.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$1.1M
- Bristol Myers Squibb$287K
- AstraZeneca$285K
- Genentech, Inc.$255K
- Acerta Pharma LLC$178K
- Janssen Research & Development, LLC$159K
- plus $249K from 7 others
What the payments were for
- Consulting fees$46,51887%
- Speaking & faculty fees$2,3474%
- Travel & lodging$3,4697%
- Food & beverage$1,0042%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 23 | $32,848 |
| AstraZeneca | 7 | $10,361 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $3,402 |
| F. Hoffmann-la Roche AG | 1 | $2,347 |
| Johnson & Johnson | 1 | $1,550 |
| Novartis | 2 | $1,384 |
| Janssen Global Services, LLC | 1 | $1,010 |
| Stemline Therapeutics Inc. | 1 | $176 |
| Bristol Myers Squibb | 3 | $87 |
| AbbVie | 4 | $61 |
| Merck | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Pfizer | 1 | $19 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Seagen Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,358 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 82 | $1,247,044 |
| ImbruvicaIbrutinib | 47 | $1,163,366 |
| BrukinsaZanubrutinib | 63 | $837,334 |
| RevlimidLenalidomide | 19 | $471,359 |
| VenclextaVenetoclax | 28 | $406,252 |
| EliquisApixaban | 13 | $7,528 |
| Atovaquone | 15 | $3,611 |
| ValacyclovirValacyclovir Hcl | 46 | $1,746 |
| Acyclovir | 108 | $1,712 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 95 | $412 |
| Fluconazole | 12 | $267 |
| Pantoprazole Sodium | 20 | $257 |
| Ciprofloxacin Hcl | 14 | $208 |
| Famotidine | 13 | $122 |
| Prochlorperazine Maleate | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $10,361 | $1,247,04482 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $3,402 | $1,163,36647 claims |
| Bristol Myers SquibbRevlimid | $87 | $471,35919 claims |
| AbbVieVenclexta | $61 | $406,25228 claims |
| PfizerEliquis | $19 | $7,52813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Hackensack
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.